Micro CT Image Showing Heterotopic Ossification in FOP Mouse Model
Learn About Our Activin A Program
Collaborate With Us

Regeneron is developing a novel investigational therapy that may halt heterotopic ossification and prevent new heterotopic bone from forming in people living with FOP

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare disabling genetic disease of heterotopic ossification (HO) of muscles, tendons, and other soft tissues that has no effective treatment.  Building on discoveries in our mouse model of FOP, Regeneron is currently developing a novel investigational therapy that may halt heterotopic ossification and prevent new heterotopic bone from forming in people living with FOP. Our novel investigational therapy has received orphan drug designation from both the U.S. Food and Drug Adminstration and the European Medicines Agency.  For more information on our research findings, click here.

We are interested in engaging with licensed medical professionals caring for people with FOP as well as potential investigators to identify the right people with FOP for clinical trials with our investigational product. If you are interested in being involved in our upcoming clinical program, click here.  We are also interested in collaborating with scientists involved in FOP research. If you are a scientist in FOP research who is interested in collaborating with us, click here.

Who We Are

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Medical Information 1-844-MID-REGN (1-844-643-7346) 8am-8pm EST Mon-Fri
I am a licensed medical professional and would like to participate in Regeneron's FOP clinical research program

Licensed medical professionals may indicate interest in participating in Regeneron’s FOP clinical research program by contacting our Medical Information Department on 1-844-MID-REGN (1-844-643-7346) Monday through Friday 8am - 8pm EST or by filling out the form below.

I am a scientist and would like to collaborate with Regeneron in FOP research

Scientists may indicate interest in collaborating with Regeneron in FOP research by contacting our Medical Information Department on 1-844-MID-REGN (1-844-643-7346) Monday through Friday 8am - 8pm EST or by filling out the form below.

I would like additional information about Regeneron’s FOP Program

Licensed medical professionals and scientists may request specific information about FOP and Regeneron’s FOP program by contacting our Medical Information Department on 1-844-MID-REGN (1-844-643-7346) Monday through Friday 8am - 8pm EST or by filling out the form below.

You Are Now Leaving the Activin A & FOP Website
This site is intended for licensed medical professionals and research scientists only. You are being directed to IFOPA’s website, which contains general reference information regarding FOP. If you have specific questions regarding Regeneron’s FOP research program, please have your doctor contact our Medical Information Department on 1-844-MID-REGN (1-844-643-7346) 8am - 8pm EST Mon-Fri.
I HAVE FOP OR AM A CAREGIVER
FOR SOMEONE WITH FOP